Literature DB >> 9646325

Developmental expression of cytochrome P450 enzymes in human liver.

J Hakkola1, E Tanaka, O Pelkonen.   

Abstract

Drug-metabolizing cytochrome P450 enzymes, the major phase I enzymes, are active in human liver already at very early stages of intrauterine development, although presumably at fairly low concentrations and in low numbers. During maturation, these enzymes go through various developmental programmes towards adulthood. The major increase both in abundance as well as in number of different enzymes takes place after birth, probably during the first year of life. Detailed information concerning these developmental changes is still limited. The major drug-metabolizing P450 enzymes appear to be primarily members of the CYP3A subfamily in all stages of development. The balance between different members of this subfamily, however, undergoes significant switches from the foetal predominant CYP3A7 to the major adult form CYP3A4. The ontogeny of the other cytochrome P450 enzymes is less well characterized, but the major switch-on appears to occur mainly after birth. Developmental expression of P450 enzymes is one of the key factors determining the pharmacokinetic status of developing individuals both pre- and postnatally.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9646325     DOI: 10.1111/j.1600-0773.1998.tb01427.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  27 in total

1.  Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Authors:  Xia Yang; Bin Zhang; Cliona Molony; Eugene Chudin; Ke Hao; Jun Zhu; Andrea Gaedigk; Christine Suver; Hua Zhong; J Steven Leeder; F Peter Guengerich; Stephen C Strom; Erin Schuetz; Thomas H Rushmore; Roger G Ulrich; J Greg Slatter; Eric E Schadt; Andrew Kasarskis; Pek Yee Lum
Journal:  Genome Res       Date:  2010-06-10       Impact factor: 9.043

Review 2.  Molecular mechanisms underlying chemical liver injury.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Expert Rev Mol Med       Date:  2012-02-03       Impact factor: 5.600

Review 3.  Linking the Epigenome with Exposure Effects and Susceptibility: The Epigenetic Seed and Soil Model.

Authors:  Emma C Bowers; Shaun D McCullough
Journal:  Toxicol Sci       Date:  2016-10-20       Impact factor: 4.849

Review 4.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 5.  Early-life exposure to EDCs: role in childhood obesity and neurodevelopment.

Authors:  Joseph M Braun
Journal:  Nat Rev Endocrinol       Date:  2016-11-18       Impact factor: 43.330

Review 6.  Liver 'organ on a chip'.

Authors:  Colin H Beckwitt; Amanda M Clark; Sarah Wheeler; D Lansing Taylor; Donna B Stolz; Linda Griffith; Alan Wells
Journal:  Exp Cell Res       Date:  2017-12-29       Impact factor: 3.905

7.  Genetic and epigenetic regulation and expression signatures of glutathione S-transferases in developing mouse liver.

Authors:  Julia Yue Cui; Supratim Choudhuri; Tamara R Knight; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2010-04-15       Impact factor: 4.849

8.  Prenatal administration of the cytochrome P4501A inducer, Β-naphthoflavone (BNF), attenuates hyperoxic lung injury in newborn mice: implications for bronchopulmonary dysplasia (BPD) in premature infants.

Authors:  Xanthi I Couroucli; Yan-hong Wei Liang; Weiwu Jiang; Lihua Wang; Roberto Barrios; Peiying Yang; Bhagavatula Moorthy
Journal:  Toxicol Appl Pharmacol       Date:  2011-06-26       Impact factor: 4.219

Review 9.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  A high-fat high-energy diet influences hepatic CYP3A expression and activity in low-birth-weight developing female rats.

Authors:  Shao-Qing Ni; Yin Lou; Xiu-Min Wang; Zheng Shen; Jue Wang; Zheng-Yan Zhao; Su Zeng
Journal:  World J Pediatr       Date:  2016-06-30       Impact factor: 2.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.